RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
Status:
Active, not recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and effectiveness of the Ranger™ Paclitaxel Coated Balloon for
treating lesions located in the superficial femoral and proximal popliteal arteries
(SFA/PPA).
Long Balloon substudy: To evaluate the safety and effectiveness of the Boston Scientific
Corporation (BSC) Ranger™ Paclitaxel Coated Balloon in the 120, 150 and 200 mm lengths for
treating Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) lesions.